Article Text

Download PDFPDF

Can we prescribe TMP/SMX prophylaxis without any concerns equally for all patients with rheumatic disease?
  1. Yasuhiro Suyama1,2,
  2. Masato Okada2
  1. 1 Division of Rheumatology, JR Tokyo General Hospital, Tokyo, Japan
  2. 2 Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University, Tokyo, Japan
  1. Correspondence to Dr Yasuhiro Suyama, Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University, Tokyo, Japan; y-suyama{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with great interest the recent article by Park et al 1 and appreciate the authors’ efforts to assess the benefit and safety of trimethoprim-sulfamethoxazole (TMP/SMX) as primary prophylaxis for pneumocystis pneumonia in patients with rheumatic diseases, exposed to prolonged high-dose glucocorticoids.

However, we would like to point out one concern in the incidence of adverse drug reactions related to TMP/SMX prophylaxis. Despite its efficacy, TMP/SMX could induce adverse events that could cause some patients to discontinue prophylaxis and increase the risk for Pneumocystis jirovecii pneumonia. There could be a disease gap for the development of adverse events, and higher risk was indicated in patients with systemic lupus erythematosus (SLE) compared with other rheumatic diseases. In patients with SLE, the reaction rate was estimated to be up to 27.3%–53%2–5 and anti-Ro/SS-A antibody was especially warned to be a prognostic factor.2 In addition, a prophylactic regimen is also important to assess safety. This is because adverse events requiring discontinuation of TMP/SMX prophylaxis were higher in patients with usual prophylaxis of a single-strength TMP/SMX tablet daily compared with graded administration.2 6 For these reasons, detailed description revealing safety profiles based on individual diseases and prophylactic regimens would be required.

In conclusion, we acknowledge the interesting results provided by the authors, confirming the safety and efficacy of TMP/SMX prophylaxis. However, we believe that evaluating safety in patients with SLE would guide the readers in having a better understanding regarding the TMP/SMX prophylaxis in patients with rheumatic diseases.



  • Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles